264 related articles for article (PubMed ID: 19262110)
1. "Armed" oncolytic herpes simplex viruses for brain tumor therapy.
Todo T
Cell Adh Migr; 2008; 2(3):208-13. PubMed ID: 19262110
[TBL] [Abstract][Full Text] [Related]
2. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
4. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
5. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
Miao L; Fraefel C; Sia KC; Newman JP; Mohamed-Bashir SA; Ng WH; Lam PY
Br J Cancer; 2014 Jan; 110(1):94-106. PubMed ID: 24196790
[TBL] [Abstract][Full Text] [Related]
6. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
Ino Y; Saeki Y; Fukuhara H; Todo T
Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
[TBL] [Abstract][Full Text] [Related]
7. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Hum Cell; 2002 Sep; 15(3):151-9. PubMed ID: 12703545
[TBL] [Abstract][Full Text] [Related]
9. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.
Nawa A; Luo C; Zhang L; Ushjima Y; Ishida D; Kamakura M; Fujimoto Y; Goshima F; Kikkawa F; Nishiyama Y
Curr Gene Ther; 2008 Jun; 8(3):208-21. PubMed ID: 18537595
[TBL] [Abstract][Full Text] [Related]
10. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
11. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
Fukuhara H; Takeshima Y; Todo T
Cancer Sci; 2021 Aug; 112(8):3293-3301. PubMed ID: 34036669
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
13. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
14. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
16. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
Kahramanian A; Kuroda T; Wakimoto H
Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
[TBL] [Abstract][Full Text] [Related]
17. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
Haines BB; Denslow A; Grzesik P; Lee JS; Farkaly T; Hewett J; Wambua D; Kong L; Behera P; Jacques J; Goshert C; Ball M; Colthart A; Finer MH; Hayes MW; Feau S; Kennedy EM; Lerner L; Quéva C
Cancer Immunol Res; 2021 Mar; 9(3):291-308. PubMed ID: 33355229
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction.
Jeyaretna DS; Kuroda T
Curr Opin Mol Ther; 2007 Oct; 9(5):447-66. PubMed ID: 17932809
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic HSV-1 for the treatment of brain tumours.
Markert JM; Parker JN; Buchsbaum DJ; Grizzle WE; Gillespie GY; Whitley RJ
Herpes; 2006 Nov; 13(3):66-71. PubMed ID: 17147910
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance.
Totsch SK; Schlappi C; Kang KD; Ishizuka AS; Lynn GM; Fox B; Beierle EA; Whitley RJ; Markert JM; Gillespie GY; Bernstock JD; Friedman GK
Oncogene; 2019 Aug; 38(34):6159-6171. PubMed ID: 31289361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
